Compare LQDA & ACMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | ACMR |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | 2513 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 2020 | 2017 |
| Metric | LQDA | ACMR |
|---|---|---|
| Price | $42.61 | $59.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $41.00 | ★ $50.00 |
| AVG Volume (30 Days) | 930.9K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ 1.37 |
| Revenue | ★ $158,320,000.00 | $74,643,000.00 |
| Revenue This Year | $278.87 | $29.37 |
| Revenue Next Year | $57.13 | $23.16 |
| P/E Ratio | ★ N/A | $43.50 |
| Revenue Growth | ★ 1031.18 | 104.47 |
| 52 Week Low | $11.85 | $21.87 |
| 52 Week High | $46.67 | $71.65 |
| Indicator | LQDA | ACMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 66.91 |
| Support Level | $35.00 | $48.82 |
| Resistance Level | $46.67 | $64.79 |
| Average True Range (ATR) | 1.65 | 3.70 |
| MACD | 0.46 | 0.80 |
| Stochastic Oscillator | 92.74 | 74.78 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
ACM Research Inc supplies capital equipment developed for the semiconductor industry. The company focuses on developing differentiated process solutions that enable effective particle removal, uniform material deposition, and reliable process control for the fabricators of integrated circuits. Its product offerings include wet-cleaning, plating, furnace, PECVD, track, and other front-end processing equipment. Additionally, it develops, manufactures, and sells a range of packaging equipment to wafer assembly and packaging customers. Geographically, the company generates maximum revenue from its customers in Mainland China, and the rest from other regions.